Medical Crossfire® From Frontline to Heavily Pretreated HR+/HER2- Metastatic Breast Cancer: Expert Perspectives on Optimizing the Expanding Treatment Armamentarium

In this podcast, experts Erika P. Hamilton, MD; Giuseppe Curigliano, MD, PhD; VK Gadi, MD, PhD; Jason Aboudi Mouabbi, MD, discuss frontline, second-line, and antibody-drug conjugate therapies for the treatment of HR-positive, HER2-negative metastatic breast cancer.